December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

C4 Therapeutics, Inc. - Common Stock (NQ:CCCC)

1.769 -0.121 (-6.39%)
Streaming Delayed Price Updated: 2:10 PM EST, Feb 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about C4 Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
News headline image
C4 Therapeutics and Betta Pharmaceuticals Announce Exclusive Licensing Agreement for the Development and Commercialization in Greater China of CFT8919, an Orally Bioavailable BiDAC™ Degrader of EGFR L858R for NSCLC
From C4 Therapeutics, Inc.
Via GlobeNewswire
News headline image
Looking Into C4 Therapeutics's Return On Capital Employed ↗
 
Via Benzinga
News headline image
Expert Ratings for C4 Therapeutics ↗
 
Via Benzinga
News headline image
Recap: C4 Therapeutics Q1 Earnings ↗
 
Via Benzinga
News headline image
C4 Therapeutics Reports First Quarter 2023 Financial Results and Recent Business Highlights
From C4 Therapeutics, Inc.
Via GlobeNewswire
News headline image
Where C4 Therapeutics Stands With Analysts ↗
 
Via Benzinga
News headline image
Looking Into C4 Therapeutics's Return On Capital Employed ↗
 
Via Benzinga
C4 Therapeutics's Return On Capital Employed Overview ↗
 
Via Benzinga
News headline image
C4 Therapeutics: Q3 Earnings Insights ↗
C4 Therapeutics (NASDAQ:CCCC) reported its Q3 earnings results on Thursday, November 3, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
News headline image
C4 Therapeutics to Participate in the Stifel 2023 Virtual Targeted Oncology Days
From C4 Therapeutics, Inc.
Via GlobeNewswire
News headline image
Why Fulcrum Therapeutics Shares Are Trading Lower By Over 55%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗
Gainers Bridger Aerospace Group Holdings, Inc. (NASDAQ: BAER) shares jumped 129.6% to $10.15. Jeffrey E. Kelter reported a 22.4% stake in a 13D filing on Thursday. 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For February 24, 2023 ↗
 
Via Benzinga
News headline image
C4 Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Business Highlights
From C4 Therapeutics, Inc.
Via GlobeNewswire
News headline image
C4 Therapeutics to Present at Two Virtual February 2023 Conferences
From C4 Therapeutics, Inc.
Via GlobeNewswire
News headline image
Ford, Atlassian, Amazon And Other Big Stocks Moving Lower On Friday ↗
U.S. stocks traded lower, with the Dow Jones dropping over 100 points on Friday. Here are some big stocks recording losses in today’s session. 
Via Benzinga
News headline image
C4 Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating CFT1946, an Orally Bioavailable BiDAC™ Degrader, in BRAF V600 Mutant Solid Tumors
From C4 Therapeutics, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
 
Via Benzinga
News headline image
C4 Therapeutics Announces 2023 Strategic Priorities to Advance Portfolio of Targeted Protein Degradation Medicines
From C4 Therapeutics, Inc.
Via GlobeNewswire
News headline image
C4 Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
From C4 Therapeutics, Inc.
Via GlobeNewswire
News headline image
Why Canoo Shares Are Trading Higher By Over 12%? Here Are 32 Stocks Moving In Friday's Mid-Day Session ↗
Gainers Peak Bio, Inc. (NYSE: PKBO) shares jumped 49.1% to $7.08. 
Via Benzinga
News headline image
Why Cosmos Health Shares Are Trading Lower By Around 60%? Here Are 79 Stocks Moving In Monday's Mid-Day Session ↗
Gainers Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) shares jumped 259% to $229.35 after the company announced resmetirom achieved both primary endpoints in NASH and liver fibrosis trial. 
Via Benzinga
News headline image
US Stocks Mixed On Black Friday; Dow Rises Over 100 Points ↗
U.S. stocks traded mixed this morning, with the Dow Jones gaining more than 100 points on Friday. Equity markets will close early on Black Friday, the day after Thanksgiving. 
Via Benzinga
News headline image
Why Coupa Software Shares Jumped Around 29%; Here Are 72 Biggest Movers From Wednesday ↗
Gainers Kalera Public Limited Company (NASDAQ: KAL) jumped 76.9% to close at $0.1610 on Wednesday after gaining 9% on Tuesday. Kalera recently posted a Q3 loss of $0.05 per share. 
Via Benzinga
News headline image
Credit Suisse, Autodesk And Other Big Losers From Wednesday ↗
U.S. stocks closed higher on Wednesday, with the Nasdaq Composite gaining more than 100 points. Here is the list of some big stocks recording losses in the previous session. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For November 4, 2022 ↗
Upgrades 
Via Benzinga
News headline image
C4 Therapeutics Reports Third Quarter 2022 Financial Results and Recent Business Highlights
From C4 Therapeutics, Inc.
Via GlobeNewswire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For October 11, 2022 ↗
Upgrades 
Via Benzinga
News headline image
C4 Therapeutics Receives Study May Proceed Letter from U.S. FDA to Initiate Phase 1/2 Clinical Trial of CFT1946, an Orally Bioavailable BiDAC™ Degrader, in BRAF-V600 Mutant Solid Cancers
Phase 1/2 Clinical Trial Will Study CFT1946 in BRAF-V600 Mutant Solid Cancers Including Lung, Colorectal and Melanoma; Trial Initiation Expected by Year End 2022 
From C4 Therapeutics, Inc.
Via GlobeNewswire
News headline image
Why Aditxt Shares Dipped Over 58%; Here Are 82 Biggest Movers From Friday ↗
Gainers Panbela Therapeutics, Inc. (NASDAQ: PBLA) shares jumped 53% to close at $0.58 on Friday. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.